Erbitux Trial Awaits Judge’s Decision

Law360, New York (July 21, 2006, 12:00 AM EDT) -- After hearing closing arguments on Wednesday, a Manhattan district court judge must now decide whether three Israeli scientists should be named co-inventors of the blockbuster cancer drug Erbitux.

The judge’s decision could have far-reaching consequences for ImClone Systems Inc., which is in danger of losing both its marketing exclusivity rights and the license for the drug itself.

In the suit, originally filed in 2003, the three scientists from Yeda Research and Development Co. claim a former colleague stole their idea and kept them off the Erbitux...
To view the full article, register now.